CITED2, widely expressed, binds competitively to the CH1 domain of CBP/p300, a transcriptional co-activator, counteracting HIF-1, which is essential for tumor cell adaptation to hypoxic environments [35]. This evidence concerns the gene SUCO and neoplasm.